More on CLRB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.21 |
|
|||
| Open | $1.21 | ||||
| 52 Wk High | $6.03 | ||||
| 52 Wk Low | $0.41 | ||||
| Day High | $1.21 | ||||
| Day Low | $1.21 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 9,561 | ||||
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
- Cellectar reports 8-year complete response in DLBCL patient using iopofosine
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
- Cellectar reports Phase 2b subgroup data for iopofosine I 131 in WM
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works
- Cellectar to present Phase 2 iopofosine data at WM workshop
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho
- Form SCHEDULE 13G Cellectar Biosciences, Filed by: Caligan Partners LP
- Form SCHEDULE 13G Cellectar Biosciences, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC
- Form SCHEDULE 13G Cellectar Biosciences, Filed by: STEMPOINT CAPITAL LP
Entities mentioned with CLRB
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Ladenburg Thalmann Financial Services | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
